Benralizumab effectiveness in patients with severe eosinophilic asthma.

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-091
• By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
• Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, Santander, Spain)
  Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
  Mrs Julia Sanchez Gundin, Hospital Pharmacist
  Mrs Marta Valero Dominguez, Hospital Pharmacist
  
• Abstract:

  Background
  Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa). It binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with high affinity and specificity.
  The IL-5Rα is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login